Abstract
Several types of B-cell malignancy, including but not limited to multiple myeloma and follicular lymphoma, are still considered incurable. In a substantial number of cases, patients must undergo either autologous or allogeneic stem cell transplantation as a standard of care procedure for their disease. Among experimental treatments for multiple myeloma and follicular lymphoma, idiotypic vaccination has been attempted over the last two decades with variable degrees of success. Few clinical trials have combined stem cell transplant procedures with idiotypic vaccination, and they are the subject of this review, which will also include some of our original data, as well as our overall evaluation of this field of clinical investigation. Although apparently at the opposite extremes of the therapeutic option array, toxicity-burdened stem cell transplantation and virtually innocuous idiotypic vaccination might well offer a sound curative opportunity to some patients with otherwise incurable B-cell malignancies, provided that the latter treatment first succeeds at obtaining regulatory approval.
Keywords: vaccine therapy, self tolerance mechanisms, prophylaxis, tumor-specific idiotype epitopes, efficacious, B-cell malignancy, idiotypic vaccination, stem cell transplant, allogeneic, autologous, lymphoma, Myeloma
Current Topics in Medicinal Chemistry
Title: Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies
Volume: 11 Issue: 13
Author(s): Maurizio Bendandi, Fernando Pastor, Jose' Nieto, Elena Soria, Helena Villanueva, Antonia Sampol, Ascension Lopez-Diaz de Cerio and Susana Inoges
Affiliation:
Keywords: vaccine therapy, self tolerance mechanisms, prophylaxis, tumor-specific idiotype epitopes, efficacious, B-cell malignancy, idiotypic vaccination, stem cell transplant, allogeneic, autologous, lymphoma, Myeloma
Abstract: Several types of B-cell malignancy, including but not limited to multiple myeloma and follicular lymphoma, are still considered incurable. In a substantial number of cases, patients must undergo either autologous or allogeneic stem cell transplantation as a standard of care procedure for their disease. Among experimental treatments for multiple myeloma and follicular lymphoma, idiotypic vaccination has been attempted over the last two decades with variable degrees of success. Few clinical trials have combined stem cell transplant procedures with idiotypic vaccination, and they are the subject of this review, which will also include some of our original data, as well as our overall evaluation of this field of clinical investigation. Although apparently at the opposite extremes of the therapeutic option array, toxicity-burdened stem cell transplantation and virtually innocuous idiotypic vaccination might well offer a sound curative opportunity to some patients with otherwise incurable B-cell malignancies, provided that the latter treatment first succeeds at obtaining regulatory approval.
Export Options
About this article
Cite this article as:
Bendandi Maurizio, Pastor Fernando, Nieto Jose', Soria Elena, Villanueva Helena, Sampol Antonia, Lopez-Diaz de Cerio Ascension and Inoges Susana, Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies, Current Topics in Medicinal Chemistry 2011; 11 (13) . https://dx.doi.org/10.2174/156802611796117676
DOI https://dx.doi.org/10.2174/156802611796117676 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucosidase II and MRH-Domain Containing Proteins in the Secretory Pathway
Current Protein & Peptide Science Patent Selections
Recent Patents on Anti-Infective Drug Discovery Role of Ox-LDL and LOX-1 in Atherogenesis
Current Medicinal Chemistry An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Targeting the Hedgehog Pathway: The development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway
Mini-Reviews in Medicinal Chemistry Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Subject Index To Volume 9
Combinatorial Chemistry & High Throughput Screening Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Synthesis of Benzophenonehydrazone Schiff Bases and their In Vitro Antiglycating Activities
Medicinal Chemistry The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Current Pharmaceutical Design Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line
Letters in Drug Design & Discovery Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Non-Integrating Lentiviral Vectors
Current Gene Therapy Peptide Nucleic Acids with a Structurally Biased Backbone. Updated Review and Emerging Challenges
Current Topics in Medicinal Chemistry